Trial Profile
An Open-label, Non-randomized, Multicenter Phase I Study to Characterize the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of Oral MKNK1 Inhibitor BAY 1143269 Given Alone or in Combination With Intravenous Docetaxel in Subjects With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BAY 1143269 (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 02 Jun 2017 Status changed from suspended to discontinued.
- 04 May 2016 Status changed from recruiting to suspended.
- 16 Jul 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.